WITHDRAWN: Bromocriptine for unexplained subfertility in women.

Abstract

BACKGROUND:

Bromocriptine improves hyperprolactinemic amenorrhea and so could also be helpful in the treatment of unexplained subfertility in women.

OBJECTIVES:

To assess the effects of bromocriptine in women with unexplained subfertility.

SEARCH STRATEGY:

The Cochrane Subfertility Review Group specialised register of controlled trials was searched.

SELECTION CRITERIA:

Randomised trials comparing bromocriptine with placebo or no treatment in women with unexplained subfertility.

DATA COLLECTION AND ANALYSIS:

Two reviewers applied the eligibility criteria and assessed trial quality independently.

MAIN RESULTS:

Three trials involving of 127 women were included. All trials were double-blind comparisons with placebo, and one was of crossover design. Conception rates with bromocriptine treatment did not improve compared with placebo (odds ratio was 1.12, 95% confidence interval 0.48 to 2.57).

AUTHORS' CONCLUSIONS:

There is not enough evidence to evaluate bromocriptine use in women with unexplained subfertility. However trials for women with unexplained subfertility who also have expressible galactorrhea may be worthwhile.

• Authors: E Hughes, J Collins, P Vandekerckhove
• Journal: The Cochrane database of systematic reviews (Cochrane Database Syst Rev) Issue 4 Pg. CD000044 (Jul 18 2007) ISSN: 1469-493X [Print] England
• PMID: 17636576 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Hormone Antagonists
• Bromocriptine

Topics

• Bromocriptine (therapeutic use)
• Female
• Hormone Antagonists (therapeutic use)
• Humans
• Infertility, Female (drug therapy)